التفاصيل البيبلوغرافية
| العنوان: |
ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS |
| Document Number: |
20080045571 |
| تاريخ النشر: |
February 21, 2008 |
| Appl. No: |
11/840953 |
| Application Filed: |
August 18, 2007 |
| مستخلص: |
The present invention relates to new compounds of formula I, [chemical expression included] to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders. |
| Inventors: |
Edwards, Louise (Mississauga, CA); Isaac, Methvin (Brampton, CA); Johansson, Martin (Sodertalje, SE); Kers, Annika (Sodertalje, SE); Malmberg, Johan (Sodertalje, SE); McLeod, Donald (Salt Lake City, UT, US); Mindis, Alexander (Sodertalje, SE); Staaf, Karin (Sodertalje, SE); Slassi, Abdelmalik (Mississauga, CA); Stefanac, Tomislav (Burlington, CA); Stormann, Thomas (Salt Lake City, UT, US); Wensbo, David (Sodertalje, SE); Xin, Tao (Toronto, CA); Arora, Jalaj (Cambridge, CA) |
| Assignees: |
AstraZeneca AB (Sodertalje, SE), NPS PHARMACEUTICALS INC. (Salt Lake City, UT, US) |
| Claim: |
1. A compound selected from the group consisting of the compounds set forth in the following table: [table included] or a pharmaceutically acceptable salt thereof. |
| Claim: |
2-11. (canceled) |
| Claim: |
12. A method of prevention and/or treatment of mGluR5 receptor-mediated disorders, comprising administering to a mammal in need of such prevention and/or treatment a therapeutically effective amount of a compound according to claim 1. |
| Claim: |
13. The method according to claim 12, wherein the disorder is a neurological disorder. |
| Claim: |
14. The method according to claim 12, wherein the disorder is a psychiatric disorder. |
| Claim: |
15. The method according to claim 12, wherein the disorder is selected from chronic and acute pain disorders. |
| Claim: |
16. The method according to claim 12, wherein the disorder is a gastrointestinal disorder. |
| Claim: |
17. The method according to claim 12, wherein the disorder is selected from the group consisting of Alzheimer's disease, senile dementia, AIDS-induced dementia, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's Chorea, migraine, epilepsy, schizophrenia, depression, anxiety, acute anxiety, obsessive compulsive disorder, opthalmological disorders, diabetic retinopathies, glaucoma, auditory neuropathic disorders, chemotherapy induced neuropathies, post-herpetic neuralgia and trigeminal neuralgia, tolerance, dependency, addiction and craving disorders, neurodevelopmental disorders, autism, mental retardation, schizophrenia, Down's Syndrome, pain related to migraine, inflammatory pain, neuropathic pain disorders, arthritis and rheumatoid diseases, low back pain, post-operative pain, pain associated with angina, renal and biliary colic, menstruation, migraine gout, stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, cardiovascular diseases and epilepsy. |
| Claim: |
18. A method for inhibiting the activation of mGluR5 receptors, comprising treating a cell containing said receptor with an effective amount of a compound according to claim 1. |
| Claim: |
19. A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of the compound according to claim 1 in association with one or more pharmaceutically acceptable diluents, excipients and/or inert carriers. |
| Current U.S. Class: |
514340/000 |
| Current International Class: |
61; 61; 61; 61; 61; 61; 61; 61; 07; 12; 07; 61; 61; 61; 61; 61; 61 |
| رقم الانضمام: |
edspap.20080045571 |
| قاعدة البيانات: |
USPTO Patent Applications |